The latest biotech news

News and Trends 23 May 2018

Grass Pollen Allergy Vaccine Gets Encouraging Phase II Results

Allergy Therapeutics has obtained positive Phase II results for its grass pollen allergy vaccine and plans to launch a Phase III study next year. British biotech Allergy Therapeutics has obtained positive Phase II results for its grass pollen allergy vaccine. Roughly 30% of the population in Europe are allergic to grass pollen. The company plans […]

May 23, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 23 May 2018

Belgian Biotech Gets a €46M Boost to Keep up in the CAR-T Race

Update (23/05/2018): Investors have fully subscribed Celyad’s global offering of shares on NASDAQ and Euronext Paris, making the company raise a total of $54.4M (€46M) to support the development of its CAR-T technology. 18/05/2018 Celyad has raised €40M ($47M) in a global offering, which could help the company keep up with large competitors amidst recent large […]

May 23, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 22 May 2018

Celgene Partners With German Biotech to Develop Oncology Treatments

Evotec has entered into a collaboration with Celgene to identify new therapeutics in oncology with a focus on solid tumors. Evotec, based in Hamburg, has received an upfront payment of $65M (€55M) from US-based Celgene, one of the largest biotechs worldwide. The funding will be used to identify potential new cancer treatments with a focus on […]

May 22, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 16 May 2018

Swedish Biotech Partners With Novo Nordisk to Advance Stem Cell Therapies for Diabetes

BioLamina has partnered with Novo Nordisk to develop stem cell therapies for diabetes and other conditions using a unique cell culture matrix technology. BioLamina, based in Stockholm, is collaborating with the world-leader in diabetes treatment Novo Nordisk to develop stem cell therapies that use BioLamina’s protein cell culture matrices. BioLamina’s technology could enhance Novo Nordisk’s […]

May 16, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 16 May 2018

Actelion’s Billion-Euro Spin-Off Starts First Phase III Trial in its Pipeline

Idorsia has started the first Phase III study in its pipeline to test the drug in patients with a life-threatening genetic disorder, which could bring the company closer to a market launch and profitability. Swiss biotech Idorsia has started a Phase III trial testing its lead compound in patients with Fabry disease, a life-threatening genetic disorder […]

May 16, 2018 - 3 minutesmins - By Alexander Burik

News and Trends 15 May 2018

Series B Funding Helps Dutch Biotech Fight Graft Versus Host Disease

Xenikos has raised $30M (€25M) in Series B funding to conduct Phase III trials for its treatment for acute graft-versus-host disease, a complication of stem cell transplants. Xenikos has raised a substantial Series B fundraising round to conduct Phase III trials in the US and the EU for T-Guard, its treatment for steroid-resistant acute graft […]

May 15, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 15 May 2018

Swiss Company Raises Ambitious IPO to Fight Antibiotic Resistance

Polyphor has closed an IPO of CHF 165M (€138M) to continue developing a new class of antibiotics against pneumonia, as well as treatments for cystic fibrosis and breast cancer. Polyphor, based in Switzerland, has raised a substantial IPO of CHF 165M (€138M) on the SIX Swiss Exchange, surpassing its initial goal of CHF150M (€127M). The funds will […]

May 15, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 15 May 2018

An Epigenetic Drug for Prostate Cancer Gets $26M to Enter Clinical Trials

CellCentric has raised a private round to fund the development of a first-in-class drug with potential to tackle treatment-resistant prostate cancer. Cambridge-based CellCentric has raised $26M from Morningside Venture Investments. The company plans to use the cash to fund the development of an epigenetic cancer drug up to Phase 2b trials. The drug in question, called CCS1477, […]

May 15, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 14 May 2018

German Biotech Expands Oncology Deal with Bluebird bio to $1.5Bn

Medigene and bluebird bio are increasing the number of cancer targets against which to develop TCR candidates, raising their already huge deal to a massive $1.5Bn. In September 2016, Medigene and bluebird bio partnered to develop T cell receptor-modified T cells (TCR-Ts) as candidates for cancer immunotherapy treatments. Medigene was offered up to $250M per each of […]

May 14, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 9 May 2018

Swiss Spin-off Secures Funding for Antibodies to Reach Difficult Targets

Memo Therapeutics has raised CHF 5M (€4,2M) to develop its antibody detection technology, which uses whole antibodies to reach difficult targets. Memo Therapeutics, a spin-off from ETH Zurich, has closed a Series A2 round of CHF 5M (€4,2M). The funding was provided by Redalpine Venture Partners and Zurich Cantonal Bank among other investors and will […]

May 9, 2018 - 1 minutemin - By Alexander Burik

News and Trends 8 May 2018

Scottish Biotech Boosts its CAR-T Pipeline for Cancer and HIV

TC Biopharm has partnered with Scotia Biologics to produce tumor-specific antibodies for a new generation of safer CAR-T therapies against multiple types of tumors as well as viral infections such as HIV. The Scottish biotech TC Biopharm will be working with its new partner Scotia Biologics on the development of CAR-T therapy candidates against neuroblastoma, […]

May 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 4 May 2018

Bionic Implant to Restore Vision Raises Funding to Complete First Human Trial

Pixium Vision has raised €10.6M by offering new shares on Euronext Paris. The funding will be used to develop its bionic vision device further and bring it closer to a European market authorization. Pixium Vision, based in Paris, has raised €10.6M on Euronext Paris to continue the first clinical study of its PRIMA bionic vision system in […]

May 4, 2018 - 2 minutesmins - By Alexander Burik

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Grass Pollen Allergy Vaccine Gets Encouraging Phase II Results

Belgian Biotech Gets a €46M Boost to Keep up in the CAR-T Race

Celgene Partners With German Biotech to Develop Oncology Treatments

Swedish Biotech Partners With Novo Nordisk to Advance Stem Cell Therapies for Diabetes

Actelion’s Billion-Euro Spin-Off Starts First Phase III Trial in its Pipeline

Series B Funding Helps Dutch Biotech Fight Graft Versus Host Disease

Swiss Company Raises Ambitious IPO to Fight Antibiotic Resistance

An Epigenetic Drug for Prostate Cancer Gets $26M to Enter Clinical Trials

German Biotech Expands Oncology Deal with Bluebird bio to $1.5Bn

Swiss Spin-off Secures Funding for Antibodies to Reach Difficult Targets

Scottish Biotech Boosts its CAR-T Pipeline for Cancer and HIV

Bionic Implant to Restore Vision Raises Funding to Complete First Human Trial

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!